- DEAN FOR CLINICAL AFFAIRS
- PROFESSOR AND SYSTEM CHAIR Ophthalmology
- PROFESSOR Medicine
American Board of Internal Medicine
MD, Johns Hopkins University
Internship, Internal Medicine
New York Hospital Cornell University Med Ctr
Wilmer Eye Institute at Johns Hopkins
Residency, Internal Medicine
Johns Hopkins Hospital
Johns Hopkins Hospital
- Douglas A. Jabs, M.D., M.B.A. is Professor and Chairman of the Department of Ophthalmology at the Mount Sinai School of Medicine. He previously was the Alan C. Woods Professor of Ophthalmology and Professor of Medicine at The Johns Hopkins University School of Medicine, Professor of Epidemiology at The Johns Hopkins University Bloomberg School of Public Health, and Director of the Division of Ocular Immunology at The Wilmer Eye Institute. He received his undergraduate degree from Dartmouth College and his M.D. from The Johns Hopkins University School of Medicine. His training includes an internship in Internal Medicine at the New York Hospital-Cornell Medical Center, a residency in Internal Medicine at the Johns Hopkins Hospital, a residency in Ophthalmology at The Wilmer Eye Institute, and a fellowship in Rheumatology at The Johns Hopkins Medical Institutions. In 1984, he joined the faculty at The Johns Hopkins University School of Medicine and was promoted to Professor in both Ophthalmology and Medicine in 1993. He received a Masters of Science in Business from The John Hopkins University in 1998, and a Masters of Business Administration from The Johns Hopkins in 2000. He became Chairman of Ophthalmology at the Mount Sinai School of Medicine in March 2007.
Dr. Jabs has been recipient of such honors and awards as the Research to Prevent Blindness Olga Keith Wiess Scholar Award, Lew R. Wasserman Merit Award, the Senior Scientific Investigator Award, the American Academy of Ophthalmology Senior Honor Award, and the Ethel Baxter Award for Excellence in Research from the Sjogren's Syndrome Foundation. He has given several named lectures and is a frequent invited speaker at national and international meetings. Dr. Jabs is a member of a number of professional societies, including the American Uveitis Society, the Retina Society, the Macula Society, the American Society of Retina Specialists, the American Ophthalmological Society, and the International Uveitis Study Group. He served as President of the American Uveitis Society for 2000-2002. He served on the National Eye Institute's Visual Sciences A Study Section from 1994 to 1998 and currently is on the National Eye Institute Intramural Program Data and Safety Monitoring Committee. Dr. Jabs serves on the editorial boards of the American Journal of Ophthalmology, Retina - The Journal of Retinal and Vitreous Diseases, and Ocular Inflammation and Immunity, and from 2002 to 2007 was the executive editor for uveitis of the American Journal of Ophthalmology.
In the News
Dr. Jabs discusses uveitis in The Daily News feature The Daily Check Up.
View the PDF.
Douglas A. Jabs, M.D., M.B.A has held funding from the National Eye Institute since 1986, including both clinical and bench research activities. He is the chairman of the Studies of Ocular Complications of AIDS (SOCA) Research Group, a multicenter clinical trials and epidemiology program, which has been in existence since 1988, has conducted five randomized clinical trials on the treatment of cytomegalovirus retinitis and now chairs an ongoing multicenter, prospective, cohort study of patients with AIDS for ocular complications and visual outcomes. He also is chairman of the Multicenter Uveitis Steroid Treatment (MUST) Trial, which is a multicenter, randomized clinical trial on the treatment of severe uveitis. His other research interests include the immunopathogenesis of autoimmune ocular disease, the epidemiology, molecular biology and clinical consequences of resistant cytomegalovirus among patients being treated for cytomegalovirus retinitis, and the treatment of uveitis. He has authored or coauthored over 200 publications and 44 book chapters. His areas of expertise include the treatment of uveitis and other ophthalmic inflammatory disorders, the ocular complications of autoimmune disease, immune deficiency and immune suppression, and cytomegalovirus retinitis.
Jabs DA. AIDS and ophthalmology. Arch Ophthalmol 2008; 126: 1143-1146.
Jabs DA, Prendergast RA, Campbell AL, Lee B, Akpek EK, Gerard HC. Autoimmune Th2-mediated dacryoadenitis in MRL/MpJ mice becomes Th1-mediated in IL-4 deficient MRL/MpJ mice. Invest Ophthalmol Vis Sci 2007; 48: 5624-5629.
Jabs DA, Martin BK, Ricks MO, Forman MS. for the Cytomegalovirus Retinitis and Viral Resistance Study Group. Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcome. J Infect Dis 2006; 193: 1728-1737.
The Standardization of Uveitis Nomenclature (SUN) Working Group . Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005; 140: 509-516.
Jabs DA. Improving the reporting of clinical case series. Am J Ophthalmol 2005; 139: 900-905.
Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, Kempen JH, Murphy RL. for the Studies of Ocular Complications of AIDS Research Group. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2005; 112: 771-779.
Jabs DA, Van Natta ML, Thorne JE, Weinberg DV, Meredith TA, Kuppermann BD, Sepkowitz K, Li HK. for the Studies of Ocular Complications of AIDS Research Group. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology 2004; 111: 2224-2231.
Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 2000; 130: 469-476.
Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe JG, Louie JS, Nussenblatt RB, Stiehm RE, Tessler H, Van Gelder RN, Whitcup SM, Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130: 492-513.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Jabs during 2013 and/or 2014. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Abbott Laboratories; Alcon, Inc.; BioScience Communications; Corcept Therapeutics; GlaxoSmithKline; Novartis; Regeneron Pharmaceuticals
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Applied Genetic Technologies Corporation; Novartis
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Annenberg Building Floor 22 Room 86
1468 Madison Avenue
New York, NY 10029